Brucellar spinal epidural abscesses. Analysis of eleven cases.
Brucellar spinal epidural abscesses (BSEA) are rare and very few series of them have been reported. In order to evaluate the clinical characteristics, management and outcome of this entity, the clinical records and current status of a series of 11 patients have been retrospectively reviewed. A series of 11 patients treated for BSEA in our Service during a period of 12 years (1989-2000) have been retrospectively studied. Spinal epidural abscesses (SEA) were diagnosed by MRI, CT or at surgery. Brucellar aetiology of SEA was considered when seroagglutination tests were positive at a titre of 1/160 or higher, and/or Brucella spp. were isolated in the blood or sample cultures. Ten of the 11 cases were treated with rifampicin plus doxycycline and in the remaining patient streptomycin was added because of a poor initial response. Six patients underwent surgical decompression and debridement of the SEA. Outcome was excellent in nine cases and good in two. There was no mortality and only one patient recovered incompletely from preadmission neurological deficits. Although BSEA is considered to be an unusual complication of spondylitis, our findings show that in some cases it can follow direct haematogenous spread to the extradural space. Surgical treatment must be undertaken when major neurological deficits are present. If antibiotic treatment is chosen as the initial therapy, the possibility of sudden neurological deterioration must be taken into account. Contrary to the high morbi-mortality rates reported in pyogenic or tuberculous SEA, BSEA has a good prognosis with early diagnosis and appropriate management.
Ugarriza
L F
LF
Servicio de Neurocirugía, Hospital Universitario Infanta Cristina, Carretera de Elvas s/n, 06008, Badajoz, Spain. med007486@nacom.es
Porras
L F
LF
Lorenzana
L M
LM
Rodríguez-Sánchez
J A
JA
García-Yagüe
L M
LM
Cabezudo
J M
JM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use; D017347:Brucella melitensis / Q000302:isolation & purification; D002006:Brucellosis / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D004318:Doxycycline / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D020802:Epidural Abscess / Q000188:drug therapy / Q000382:microbiology* / Q000601:surgery; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008875:Middle Aged; D012189:Retrospective Studies; D012293:Rifampin / Q000627:therapeutic use; D013131:Spine / Q000473:pathology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000904:Antibiotics, Antitubercular; D004318:Doxycycline; D012293:Rifampin